Table 4 Fat intake in relation to risk of different histologic subtypesa of invasive EOC in the New England-based case–control studyb

From: Dietary fat intake and risk of epithelial ovarian cancer by tumour histology

 

Controls ( n =1978)

Serous ( n =842)

Endometrioid ( n =308)

Clear cell ( n =108)

Mucinous ( n =87)

 

Type of fat intake

N

N (cases)

OR

(95% CI)

N (cases)

OR

(95% CI)

N (cases)

OR

(95% CI)

N (cases)

OR

(95% CI)

P -het c

Total fat (g day–1)

Q1

494

219

1.00 (Ref)

 

78

1.00 (Ref)

 

28

1.00 (Ref)

 

24

1.00 (Ref)

 

0.72

Q2

495

186

0.87

(0.68–1.10)

73

0.96

(0.68–1.36)

20

0.73

(0.40–1.32)

17

0.72

(0.38–1.37)

 

Q3

495

219

1.03

(0.82–1.31)

67

0.89

(0.62–1.27)

29

1.07

(0.63–1.83)

27

1.16

(0.66–2.05)

 

Q4

494

218

1.05

(0.83–1.33)

90

1.22

(0.87–1.70)

31

1.17

(0.69–1.99)

19

0.84

(0.45–1.55)

 

P-trendd

  

0.42

  

0.26

  

0.35

  

0.88

  

Vegetable fat (g day–1)

Q1

493

213

1.00 (Ref)

 

81

1.00 (Ref)

 

25

1.00 (Ref)

 

23

1.00 (Ref)

 

0.63

Q2

496

182

0.82

(0.64–1.04)

78

0.92

(0.65–1.29)

20

0.76

(0.42–1.40)

25

1.04

(0.58–1.86)

 

Q3

495

206

0.98

(0.77–1.24)

67

0.83

(0.59–1.19)

30

1.21

(0.70–2.10)

20

0.88

(0.47–1.62)

 

Q4

494

241

1.04

(0.83–1.31)

82

0.93

(0.67–1.31)

33

1.22

(0.71–2.08)

19

0.76

(0.41–1.42)

 

P-trendd

  

0.39

  

0.66

  

0.25

  

0.32

  

Animal fat (g day–1)

Q1

495

230

1.00 (Ref)

 

80

1.00 (Ref)

 

36

1.00 (Ref)

 

18

1.00 (Ref)

 

0.82

Q2

494

186

0.90

(0.71–1.14)

69

0.96

(0.67–1.36)

21

0.65

(0.37–1.13)

20

1.23

(0.64–2.36)

 

Q3

495

217

1.05

(0.84–1.33)

84

1.17

(0.84–1.64)

25

0.77

(0.46–1.31)

28

1.74

(0.95–3.19)

 

Q4

494

209

1.04

(0.82–1.31)

75

1.07

(0.76–1.51)

26

0.82

(0.49–1.39)

21

1.33

(0.70–2.54)

 

P-trendd

  

0.51

  

0.50

  

0.58

  

0.28

  

Dairy fat (g day–1)

Q1

496

247

1.00 (Ref)

 

72

1.00 (Ref)

 

37

1.00 (Ref)

 

19

1.00 (Ref)

 

0.24

Q2

494

216

0.92

(0.73–1.16)

100

1.47

(1.05–2.04)

24

0.68

(0.40–1.16)

26

1.44

(0.79–2.65)

 

Q3

495

178

0.77

(0.61–0.98)

63

0.94

(0.65–1.36)

22

0.64

(0.37–1.10)

22

1.24

(0.66–2.34)

 

Q4

493

201

0.91

(0.72–1.14)

73

1.13

(0.79–1.61)

25

0.75

(0.44–1.27)

20

1.17

(0.62–2.23)

 

P-trendd

  

0.30

  

0.89

  

0.31

  

0.83

  

Trans fat (g day–1)

Q1

491

206

1.00 (Ref)

 

66

1.00 (Ref)

 

28

1.00 (Ref)

 

20

1.00 (Ref)

 

0.83

Q2

501

188

0.97

(0.76–1.23)

78

1.26

(0.88–1.79)

23

0.87

(0.49–1.54)

19

1.01

(0.53–1.92)

 

Q3

491

199

1.05

(0.82–1.33)

85

1.40

(0.98–1.98)

28

1.08

(0.63–1.86)

23

1.25

(0.67–2.31)

 

Q4

495

249

1.28

(1.02–1.62)

79

1.27

(0.89–1.81)

29

1.10

(0.64–1.88)

25

1.33

(0.72–2.43)

 

P-trendd

  

0.02

  

0.19

  

0.59

  

0.29

  

Saturated fat (g day–1)

Q1

495

229

1.00 (Ref)

 

76

1.00 (Ref)

 

36

1.00 (Ref)

 

24

1.00 (Ref)

 

0.29

Q2

494

195

0.92

(0.72–1.16)

72

1.02

(0.72–1.45)

23

0.69

(0.40–1.18)

13

0.58

(0.29–1.16)

 

Q3

492

190

0.87

(0.69–1.11)

74

1.03

(0.72–1.45)

27

0.79

(0.47–1.33)

29

1.27

(0.73–2.23)

 

Q4

497

228

1.11

(0.88–1.40)

86

1.27

(0.90–1.78)

22

0.68

(0.40–1.18)

21

0.98

(0.54–1.79)

 

P-trendd

  

0.41

  

0.18

  

0.22

  

0.59

  

Cholesterol (mg day–1)

Q1

494

219

1.00 (Ref)

 

79

1.00 (Ref)

 

30

1.00 (Ref)

 

24

1.00 (Ref)

  

Q2

495

204

0.98

(0.78–1.25)

68

0.91

(0.64–1.29)

27

0.95

(0.56–1.63)

18

0.79

(0.42–1.48)

0.50

Q3

495

193

0.91

(0.72–1.16)

90

1.18

(0.85–1.65)

24

0.83

(0.48–1.44)

27

1.17

(0.66–2.06)

 

Q4

494

226

1.06

(0.84–1.34)

71

0.93

(0.65–1.31)

27

0.93

(0.54–1.59)

18

0.77

(0.41–1.45)

 

P-trendd

  

0.68

  

0.95

  

0.72

  

0.64

  

Monounsaturated fat (g day–1)

Q1

497

216

1.00 (Ref)

 

82

1.00 (Ref)

 

27

1.00 (Ref)

 

21

1.00 (Ref)

 

0.92

Q2

493

198

0.92

(0.72–1.16)

71

0.87

(0.61–1.22)

22

0.81

(0.46–1.45)

22

1.05

(0.57–1.94)

 

Q3

494

222

1.05

(0.83–1.32)

74

0.92

(0.65–1.30)

35

1.32

(0.78–2.22)

25

1.21

(0.67–2.20)

 

Q4

494

206

0.96

(0.76–1.22)

81

1.00

(0.71–1.40)

24

0.90

(0.51–1.58)

19

0.91

(0.48–1.72)

 

P-trendd

  

0.97

  

0.93

  

0.93

  

0.88

  

Polyunsaturated fat (g day–1)

Q1

495

227

1.00 (Ref)

 

79

1.00 (Ref)

 

23

1.00 (Ref)

 

20

1.00 (Ref)

 

0.56

Q2

490

200

0.85

(0.68–1.08)

82

1.01

(0.72–1.41)

21

0.89

(0.48–1.63)

26

1.26

(0.69–2.29)

 

Q3

499

217

0.93

(0.74–1.18)

74

0.91

(0.65–1.29)

32

1.36

(0.78–2.36)

24

1.17

(0.64–2.15)

 

Q4

494

198

0.83

(0.66–1.05)

73

0.88

(0.62–1.25)

32

1.33

(0.76–2.31)

17

0.81

(0.42–1.57)

 

P-trendd

  

0.20

  

0.40

  

0.17

  

0.45

  

Long chain omega-3 ( n −3)e (g day–1)

Q1

494

216

1.00 (Ref)

 

96

1.00 (Ref)

 

24

1.00 (Ref)

 

28

1.00 (Ref)

 

0.20

Q2

495

206

0.94

(0.75–1.19)

75

0.77

(0.55–1.08)

32

1.32

(0.76–2.28)

21

0.74

(0.41–1.33)

 

Q3

495

196

0.86

(0.67–1.09)

77

0.76

(0.54–1.05)

30

1.18

(0.68–2.05)

19

0.64

(0.35–1.17)

 

Q4

494

224

0.96

(0.76–1.21)

60

0.58

(0.41–0.82)

22

0.85

(0.47–1.54)

19

0.63

(0.34–1.14)

 

P-trendd

  

0.69

  

0.003

  

0.39

  

0.13

  

Omega-6 ( n −6)e (g day–1)

Q1

494

210

1.00 (Ref)

 

82

1.00 (Ref)

 

25

1.00 (Ref)

 

25

1.00 (Ref)

 

0.06

Q2

499

226

1.06

(0.84–1.34)

72

0.87

(0.61–1.22)

15

0.59

(0.31–1.14)

21

0.83

(0.46–1.51)

 

Q3

491

208

0.97

(0.76–1.23)

87

1.04

(0.74–1.44)

40

1.56

(0.93–2.62)

26

1.01

(0.58–1.79)

 

Q4

494

198

0.90

(0.71–1.14)

67

0.78

(0.55–1.11)

28

1.07

(0.61–1.87)

15

0.57

(0.30–1.10)

 

P-trendd

  

0.27

  

0.28

  

0.28

  

0.15

  
  1. Abbreviations: CI=confidence interval; EOC=epithelial ovarian cancer; MA=Massachusetts; N (cases)=number of cases; n−3=omega-3; n−6=omega-6; NH=New Hampshire; OC=oral contraceptive; OR=odds ratio; P-het=P-value for heterogeneity; Q1, Q4=quartiles 1, 4.
  2. aInvasive EOCs classified as other/undifferentiated were excluded from this analysis.
  3. bMultivariate polytomous logistic regression models were adjusted for age (continuous), study centre (MA, NH), study phase (1992–1997, 1998–2003, 2003–2008), number of pregnancies (0, 1, 2, 3, >3), OC use (none, 3 months, <1 year, 1, 5 years, >5 years), family history of ovarian cancer and history of tubal ligation (yes/no).
  4. The P-het is from the likelihood-ratio test that compares a model with the same estimate for the association with the exposure of interest (e.g., categories of total fat intake) across histologic subtypes to a model, which allows the association with the exposure of interest to vary across the histologic subtypes.
  5. dThe P-trend is the test for trend within each histologic subtype using a trend variable based on the median intake value from each quartile based on the distribution in controls.
  6. eIntakes are from food only.
Back to article page